Catheter Precision (VTAK) EBITDA (2017 - 2026)

Catheter Precision (VTAK) has reported EBITDA for 10 consecutive years, with -$4.0 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, EBITDA rose 15.6% year-over-year to -$4.0 million in Q2 2026; TTM through Jun 2026 was -$19.2 million, a 35.17% decrease from a year earlier, with the FY2025 full-year figure at -$21.1 million, down 88.05% from the prior year.
• EBITDA was -$4.0 million for Q2 2026 at Catheter Precision, down from -$2.3 million in the prior quarter.
• Over five years, EBITDA peaked at -$2.3 million in Q1 2026 and troughed at -$66.5 million in Q1 2023.
• A 5-year average of -$8.0 million and a median of -$3.8 million in 2025 frame the typical range for EBITDA.
• Across the five-year window, EBITDA slumped 1108.14% in 2023 and surged 96.07% in 2024, its largest moves.
• Over 5 years, EBITDA stood at -$8.2 million in 2022, then surged by 68.39% to -$2.6 million in 2023, then dropped by 17.48% to -$3.1 million in 2024, then slumped by 223.21% to -$9.9 million in 2025, then surged by 59.89% to -$4.0 million in 2026.
• The last three EBITDA figures came in at -$4.0 million (Q2 2026), -$2.3 million (Q1 2026), and -$9.9 million (Q4 2025), per Business Quant data.